ESC 365 - FIGARO-DKD: finerenone in patients with chronic kidney disease and type 2 diabetes

ESC Premium Access

FIGARO-DKD: finerenone in patients with chronic kidney disease and type 2 diabetes

Session: Hot Line - FIGARO-DKD / FIDELITY Analysis

Topic: Aldosterone Antagonists

Speaker: Professor B. Pitt (Ann Arbor, US)

Event: ESC Congress 2021 - The Digital Experience

Presentation

About the speaker

Professor Bertram Pitt

University of Michigan, Ann Arbor (United States of America)

19 presentations

0 follower

5 more presentations in this session

FIGARO-DKD - Discussant review.

Speaker: Doctor K. Damman (Groningen, NL)

FIDELITY Analysis: finerenone in mild-to-severe chronic kidney disease and type 2 diabetes - Part 1

FIDELITY Analysis: finerenone in mild-to-severe chronic kidney disease and type 2 diabetes

Speaker: Professor G. Filippatos (Athens, GR)

FIDELITY Analysis - Discussant review.

Speaker: Professor C. Baigent (Oxford, GB)

FIGARO-DKD / FIDELITY Analysis - Panel discussion.

Access the full session

Hot Line - FIGARO-DKD / FIDELITY Analysis

Speakers: Professor B. Pitt, Doctor K. Damman, Professor G. Filippatos, Professor C. Baigent

About the event

ESC Congress 2021 - The Digital Experience

27 August - 30 August 2021

Sessions Presentations

Congress

Related content

ACVC Premium Access

Pharmacological treatment: how to choose your drug (if any)

19 March 2022

Open Access

A curated selection of highlights

24 October 2021

ESC Premium Access

Cardiovascular protection by combination of the selective nonsteroidal MR antagonist finerenone and the SGLT2 inhibitor empagliflozin in a preclinical model of hypertension-induced end-organ damage

27 August 2021

This platform is supported by